Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6–12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodolfo Guelman [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2023/9355672 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ081626703 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ081626703 | ||
| 003 | DE-627 | ||
| 005 | 20230310220914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2023/9355672 |2 doi | |
| 035 | |a (DE-627)DOAJ081626703 | ||
| 035 | |a (DE-599)DOAJ38d549c2501e4e82942cefc3c4549295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Rodolfo Guelman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6–12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR. | ||
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Ariel Sánchez |e verfasserin |4 aut | |
| 700 | 0 | |a Mariela Varsavsky |e verfasserin |4 aut | |
| 700 | 0 | |a Lucas R. Brun |e verfasserin |4 aut | |
| 700 | 0 | |a María Laura García |e verfasserin |4 aut | |
| 700 | 0 | |a Marcelo Sarli |e verfasserin |4 aut | |
| 700 | 0 | |a Rey Paula |e verfasserin |4 aut | |
| 700 | 0 | |a Vanina Farias |e verfasserin |4 aut | |
| 700 | 0 | |a María Belén Zanchetta |e verfasserin |4 aut | |
| 700 | 0 | |a Evangelina Giacoia |e verfasserin |4 aut | |
| 700 | 0 | |a Helena Salerni |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Maffei |e verfasserin |4 aut | |
| 700 | 0 | |a Valeria Premrou |e verfasserin |4 aut | |
| 700 | 0 | |a Beatriz Oliveri |e verfasserin |4 aut | |
| 700 | 0 | |a María Lorena Brance |e verfasserin |4 aut | |
| 700 | 0 | |a Magdalena Pavlove |e verfasserin |4 aut | |
| 700 | 0 | |a Silvia Karlsbrum |e verfasserin |4 aut | |
| 700 | 0 | |a María Silvia Larroudé |e verfasserin |4 aut | |
| 700 | 0 | |a Pablo René Costanzo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Endocrinology |d Hindawi Limited, 2009 |g (2023) |w (DE-627)DOAJ000101699 |x 16878345 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2023/9355672 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/38d549c2501e4e82942cefc3c4549295 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2023/9355672 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1687-8345 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2023 | ||